ReviewFrontiers in molecular biosciences2026
Cell- and biological-based drug delivery vectors for cancer treatment.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of cell- and biological-based (CBb) vectors for drug delivery has paved new pathways in cancer therapy, capitalizing on the distinct properties inherent to various microbial systems. In this review, we take a critical look at a range of promising drug delivery platforms, including polymeric micelles, bacterial outer membrane vesicles (OMVs), liposomes, fungi, yeast, bacteria, red blood cells stem cells, virus and microalgae. Our focus is on evaluating their efficacy, targeting capabilities, and biocompatibility. Key findings suggest that Daptomycin-Doxorubicin (Dap-DOX) micelles enhance cytotoxicity and selectively accumulate in tumors through the enhanced permeability and retention (EPR) effect. Likewise, bacterial-derived magnetosomes appear to offer significant tumor suppression and show reduced cardiac toxicity compared to traditional doxorubicin (DOX) treatments. Additionally, RBC-based systems have demonstrated effective targeting and delivery of DOX to cancer sites, surpassing the performance of free drug formulations. The discussed works mainly focused on the use of DOX, however we also reviewed papers where other chemotherapeutic agents have been used. Among the reviewed platforms, microalgae stand out as particularly promising due to their biocompatibility, poor ability to multiply inside human body, and ability to boost drug loading efficiency, facilitating targeted delivery. Evidence points to microalgae's potential to enhance the therapeutic index of anticancer drugs, as exemplified by the quick drug release behavior of cell vesicles loaded with doxorubicin in acidic tumor microenvironments. Despite these promising developments, challenges persist, especially in the optimization of microbial engineering and the scalability required for clinical applications. We suggest that microalgae offer a compelling platform for future research and development in cancer drug delivery, highlighting the need for further exploration to unlock their full potential in oncological therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.